71.05
price up icon0.69%   0.49
 
loading
Incyte Corp stock is traded at $71.05, with a volume of 2.14M. It is up +0.69% in the last 24 hours and up +7.02% over the past month. Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$70.56
Open:
$70.66
24h Volume:
2.14M
Relative Volume:
1.08
Market Cap:
$13.69B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
37.59
EPS:
1.89
Net Cash Flow:
$16.80M
1W Performance:
-11.72%
1M Performance:
+7.02%
6M Performance:
+24.24%
1Y Performance:
+29.87%
1-Day Range:
Value
$70.25
$71.68
1-Week Range:
Value
$65.02
$80.46
52-Week Range:
Value
$50.35
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
Name
Incyte Corp
Name
Phone
(302) 498-6700
Name
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Employee
2,524
Name
Twitter
@Incyte
Name
Next Earnings Date
2024-10-29
Name
Latest SEC Filings
Name
INCY's Discussions on Twitter

Compare INCY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
INCY 71.05 13.69B 4.08B 32.48M 16.80M 1.89
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Incyte Corp Stock (INCY) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-13-23 Upgrade Leerink Partners Market Perform → Outperform
Dec-04-23 Upgrade Guggenheim Neutral → Buy
Nov-21-23 Downgrade Goldman Buy → Neutral
Jul-25-23 Initiated Citigroup Buy
May-04-23 Downgrade BofA Securities Buy → Neutral
Apr-10-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-24-23 Upgrade SVB Securities Underperform → Market Perform
Jan-31-23 Initiated Piper Sandler Overweight
Aug-03-22 Downgrade Evercore ISI Outperform → In-line
Aug-03-22 Downgrade Guggenheim Buy → Neutral
Jul-28-22 Initiated Wells Fargo Equal Weight
Feb-09-22 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-18-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-19-21 Initiated BMO Capital Markets Market Perform
Jul-20-21 Upgrade The Benchmark Company Hold → Buy
Feb-10-21 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-07-21 Initiated Truist Buy
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Jun-16-20 Initiated The Benchmark Company Hold
May-06-20 Downgrade JP Morgan Overweight → Neutral
Apr-29-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-24-20 Resumed William Blair Outperform
Mar-13-20 Upgrade BofA/Merrill Neutral → Buy
Feb-04-20 Resumed BofA/Merrill Neutral
Jan-03-20 Reiterated BMO Capital Markets Market Perform
Jan-03-20 Downgrade Mizuho Buy → Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Oct-03-19 Initiated Mizuho Buy
Sep-12-19 Initiated BMO Capital Markets Market Perform
Sep-05-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Sep-05-19 Resumed Morgan Stanley Equal-Weight
Sep-05-19 Upgrade Oppenheimer Perform → Outperform
May-21-19 Initiated Credit Suisse Neutral
May-03-19 Downgrade Barclays Overweight → Equal Weight
Apr-11-19 Initiated Stifel Hold
Apr-03-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-24-19 Upgrade William Blair Mkt Perform → Outperform
View All

Incyte Corp Stock (INCY) Latest News

pulisher
Nov 20, 2024

Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Nov 20, 2024
pulisher
Nov 20, 2024

Connor Clark & Lunn Investment Management Ltd. Lowers Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

What Are Wall Street Analysts' Target Price For Incyte Stock? - Barchart

Nov 20, 2024
pulisher
Nov 20, 2024

What Are Wall Street Analysts' Target Price for Incyte Stock? - Inkl

Nov 20, 2024
pulisher
Nov 20, 2024

Merck (MRK) Eyes Incyte (INCY) for Possible Acquisition - Value the Markets

Nov 20, 2024
pulisher
Nov 20, 2024

Incyte Sinks On Setback For 2 Drugs Acquired In $750M Buyout: Retail Chatter Hits One-Year High - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch

Nov 19, 2024
pulisher
Nov 19, 2024

U.S. Indexes Ended Tuesday Mixed As Super Micro Computer Led, Incyte Lagged - Barron's

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges - AOL

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte stock maintains Outperform rating despite study pause - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte (NASDAQ:INCY) Shares Gap DownHere's Why - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Merck ‘linked’ to takeover bid for Incyte, Sky News says - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte seesaws on report of potential Merck takeover interest (NASDAQ:INCY) - Seeking Alpha

Nov 19, 2024
pulisher
Nov 19, 2024

What's Going On With Incyte Shares Tuesday? - Benzinga

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock. - MSN

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study - Investopedia

Nov 19, 2024
pulisher
Nov 19, 2024

Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte Stock Is S&P 500’s Worst Performer. Here’s Why. - Barron's

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte Faces Challenges but Remains Focused on Strategic Growth - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte sinks on setback for drugs acquired in $750M buyout - BioPharma Dive

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. - Yahoo! Voices

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte (NASDAQ:INCY) Given Neutral Rating at Cantor Fitzgerald - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte price target lowered to $86 from $90 at BofA - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

RBC maintains sector perform on Incyte shares, cuts target following '262 pause - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

One Paused, One Dropped: Incyte’s Skin Drug Acquisitions Hit Problems - Citeline News & Insights

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

Incyte culls one Escient-acquired dermatology programme, pauses another - FirstWord Pharma

Nov 19, 2024
pulisher
Nov 18, 2024

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Nov 18, 2024
pulisher
Nov 18, 2024

After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Incyte (INCY) will pause enrollment in ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria - StreetInsider.com

Nov 18, 2024
pulisher
Nov 18, 2024

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

Dr. Pimple Popper gets personal with eczema in Incyte’s Moments of Clarity push - MM+M Online

Nov 18, 2024
pulisher
Nov 17, 2024

Seizert Capital Partners LLC Has $6.24 Million Position in Incyte Co. (NASDAQ:INCY) - MarketBeat

Nov 17, 2024
pulisher
Nov 17, 2024

Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects - Insider Monkey

Nov 16, 2024
pulisher
Nov 16, 2024

Incyte Co. (NASDAQ:INCY) Shares Purchased by Mizuho Securities USA LLC - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Incyte Co. (NASDAQ:INCY) Shares Sold by Principal Financial Group Inc. - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Nov 15, 2024
pulisher
Nov 14, 2024

Incyte price target raised to $80 from $72 at RBC Capital - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

KBC Group NV Sells 563,357 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Incyte's SWOT analysis: stock faces patent cliff as pipeline progresses By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 14, 2024

Incyte to Present at Citi's 2024 Global Healthcare Conference in Miami | INCY Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

INCY (Incyte) Cash Flow from Operations : $102 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Incyte's SWOT analysis: stock faces patent cliff as pipeline progresses - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Anal Cancer Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

Anal Cancer Market Revenue to Expand Significantly by 2034, - openPR

Nov 13, 2024
pulisher
Nov 13, 2024

Incyte Co. (NASDAQ:INCY) Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

Incyte Co. (NASDAQ:INCY) Shares Sold by Amalgamated Bank - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Los Angeles Capital Management LLC Lowers Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat

Nov 12, 2024

Incyte Corp Stock (INCY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):